IONS Form 4: Bennett sells shares under 10b5-1 and exercises 46,800 options
Rhea-AI Filing Summary
C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals (IONS), reported multiple transactions in early September 2025. He sold shares under a Rule 10b5-1 trading plan adopted May 13, 2025, and reported sales on 09/02/2025 and 09/03/2025 at weighted-average prices of $49.14 and ranges around $60.25–$61.995 and $61.26–$61.995 as disclosed. On 09/03/2025 he also acquired 46,800 shares by exercise/conversion of non-qualified stock options with a $53.77 exercise price. Following the reported activity, his beneficial ownership is reported as 88,679 shares.
Positive
- Use of a Rule 10b5-1 trading plan for sales adopted May 13, 2025, which documents pre-planned disposition
- Exercise/conversion of 46,800 non-qualified stock options at a $53.77 exercise price, increasing immediately realized ownership prior to sales disclosure
Negative
- Net reduction in reported beneficial ownership following multiple sales, with reported holdings at 88,679 shares after the transactions
- Material number of shares sold (multiple tranches on 09/02–09/03/2025) at prices ranging up to $61.995, representing insider liquidity
Insights
TL;DR: Insider exercised options and executed multiple sales under a 10b5-1 plan, ending with reported beneficial ownership of 88,679 shares.
The filing documents routine insider activity: option exercise/conversion of 46,800 shares at a $53.77 exercise price and subsequent market sales across 09/02–09/03/2025. The seller used a pre-established Rule 10b5-1 plan for at least some sales, which indicates pre-planned disposition rather than opportunistic trading. The weighted-average sale prices and range disclosures are provided without additional context about tax-related or diversification motives. For investors, this is a disclosure of liquidity and option exercise but the filing itself contains no operational or financial performance data.
TL;DR: Governance-wise this is a standard Form 4 reporting exercise, sales, and use of a 10b5-1 plan with full price ranges disclosed.
The report notes that certain sales were executed pursuant to a 10b5-1 trading plan adopted May 13, 2025, and provides weighted-average prices and price ranges for multiple sale tranches. The form is signed by an attorney-in-fact, indicating delegated filing authority. There are no indications of unusual timing relative to undisclosed material events in this filing; it adheres to Section 16 reporting requirements by documenting option activity and share dispositions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 46,800 | $0.00 | -- |
| Exercise | Common Stock | 46,800 | $53.77 | $2.52M |
| Sale | Common Stock | 33,909 | $60.62 | $2.06M |
| Exercise | Common Stock | 12,891 | $61.50 | $793K |
| Sale | Common Stock | 5,000 | $49.14 | $246K |
Footnotes (1)
- Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 13, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.25 to $61.24 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.26 to $61.995 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (e) on this Form 4.
